Jonathan Dranoff, MD
he/him/his
Professor of Medicine (Digestive Diseases)DownloadHi-Res Photo
Cards
Appointments
Digestive Diseases
Primary
Additional Titles
Director, Steatotic Liver Disease Program , Digestive Diseases, VA Connecticut Healthcare System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Appointments
Digestive Diseases
Primary
Additional Titles
Director, Steatotic Liver Disease Program , Digestive Diseases, VA Connecticut Healthcare System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Appointments
Digestive Diseases
Primary
Additional Titles
Director, Steatotic Liver Disease Program , Digestive Diseases, VA Connecticut Healthcare System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
About
Copy Link
Titles
Professor of Medicine (Digestive Diseases)
Positions outside Yale
Director, Steatotic Liver Disease Program , Digestive Diseases, VA Connecticut Healthcare System
Biography
Dr. Dranoff is a professor of medicine in the Section of Digestive Diseases. Dr. Dranoff is a physician/scholar who has expertise in several areas in liver disease pathophysiology. As director of the VA Connecticut Healthcare System Steatotic Liver Disease program, he has an interests in exercise and coffee consumption as approaches to moderate the effect of steatotic liver disease. Dr. Dranoff is also interested in drug-induced liver injury, including acetaminophen safety/toxicity in patients with advanced chronic liver disease.
Last Updated on October 06, 2023.
Appointments
Digestive Diseases
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Yale University School of Medicine (1999)
- Resident
- Boston University Medical Center (1996)
- MD
- Drexel University (1993)
- BA
- Lehigh University (1991)
Research
Copy Link
Overview
Medical Research Interests
Acetaminophen; Chemical and Drug Induced Liver Injury; Fibrosis; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease
ORCID
0000-0003-3130-1909
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jonathan Dranoff's published research.
Publications Timeline
A big-picture view of Jonathan Dranoff's research output by year.
Research Interests
Research topics Jonathan Dranoff is interested in exploring.
Dhanpat Jain, MD, MBBS
Michael H Nathanson, MD, PhD
Tamar Taddei, MD
Basile Njei, MD, PhD, FRCP
Joseph Lim, MD
Sarpong Boateng
94Publications
3,967Citations
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease
Acetaminophen
Fibrosis
Publications
2026
Cannabis Use Disorder Is Associated With Increased Risk of Acute Myocardial Infarction in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Population-Based Analysis
Njei B, Boateng S, Kwentoh I, Ameyaw P, Ezeani C, Nso N, Forsah S, Dimala C, Ugwendum D, Njei L, Al-Ajlouni Y, Lim J, Dranoff J. Cannabis Use Disorder Is Associated With Increased Risk of Acute Myocardial Infarction in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Population-Based Analysis. Cureus 2026, 18: e103299. PMID: 41822655, PMCID: PMC12978627, DOI: 10.7759/cureus.103299.Peer-Reviewed Original ResearchThis study investigates the link between cannabis use disorder and heart attack risk in adults with liver disease, finding a twofold increased risk for acute myocardial infarction.
2025
Lean MASLD in U.S. Adults: Undiagnosed Burden and Metabolic Features from NHANES 2017–2020
Njei B, Boateng S, Mohamed M, Al-Ajlouni Y, Soliman M, Dranoff J, Lim J. Lean MASLD in U.S. Adults: Undiagnosed Burden and Metabolic Features from NHANES 2017–2020. Journal Of General Internal Medicine 2025, 1-9. PMID: 41402675, DOI: 10.1007/s11606-025-10086-8.Peer-Reviewed Original ResearchThis study investigates the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in lean U.S. adults, finding it affects 6.4%, with 34.6% undiagnosed, highlighting a need for improved screening in this overlooked population.Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance
Bansal M, Patton H, Morgan T, Carr R, Dranoff J, Allen A. Semaglutide therapy for metabolic dysfunction–associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology 2025, 83: 1326-1340. PMID: 41201884, DOI: 10.1097/hep.0000000000001608.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricInsulin resistance, metabolic dysfunction–associated steatotic liver disease, and advanced liver fibrosis in lean US adults: a population-based study
Njei B, Abdu M, Al-Ajlouni Y, Mohamed M, Deng Y, Osta E, Kanmounye U, Vilarinho S, Dranoff J, Lim J, Md, Echouffo Tcheugui J. Insulin resistance, metabolic dysfunction–associated steatotic liver disease, and advanced liver fibrosis in lean US adults: a population-based study. Baylor University Medical Center Proceedings 2025, 38: 637-645. PMID: 40821486, PMCID: PMC12351751, DOI: 10.1080/08998280.2025.2524199.Peer-Reviewed Original ResearchCitations
2024
Non-pharmacological Interventions for Muscle Cramps and Pain in Patients With Cirrhosis: A Systematic Review
Muller R, Dranoff J, Grimshaw A, Bastian L, Gunderson C. Non-pharmacological Interventions for Muscle Cramps and Pain in Patients With Cirrhosis: A Systematic Review. Cureus 2024, 16: e64859. PMID: 39156429, PMCID: PMC11330311, DOI: 10.7759/cureus.64859.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDiagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity
Tas E, Sundararajan D, Lo J, Morelli N, Garcia-Reyes Y, Ware M, Rahat H, Ou X, Na X, Sundaram S, Severn C, Pyle L, Børsheim E, Vajravelu M, Muzumdar R, Dranoff J, Cree M. Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity. Journal Of The Endocrine Society 2024, 8: bvae110. PMID: 38895640, PMCID: PMC11185182, DOI: 10.1210/jendso/bvae110.Peer-Reviewed Original ResearchCitationsAASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis
Sterling R, Patel K, Duarte-Rojo A, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 2024, 81: 321-357. PMID: 38489523, DOI: 10.1097/hep.0000000000000845.Peer-Reviewed Original ResearchCitationsAltmetricAASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension
Sterling R, Asrani S, Levine D, Duarte-Rojo A, Patel K, Fiel M, Leung D, Taouli B, Alsawas M, Murad M, Dranoff J, Taddei T, Rockey D. AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension. Hepatology 2024, 81: 1060-1085. PMID: 38489663, DOI: 10.1097/hep.0000000000000844.Peer-Reviewed Original ResearchCitationsAltmetricAccuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024, 81: 358-379. PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricAASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.
Sterling R, Duarte-Rojo A, Patel K, Asrani S, Alsawas M, Dranoff J, Fiel M, Murad M, Leung D, Levine D, Taddei T, Taouli B, Rockey D. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 2024, 81: 672-724. PMID: 38489518, DOI: 10.1097/hep.0000000000000843.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
Copy Link
Activities
activity National Institutes of Health
02/08/2021 - PresentPeer Review Groups and Grant Study SectionsMemberDetailsRegular member, DDK-C Study Sectionactivity American Association for the Study of Liver Disease
2015 - 2017Peer Review Groups and Grant Study SectionsChairpersonDetailsChair, Liver Fibrosis Special Interest Groupactivity National Institutes of Health
02/09/2009 - 02/04/2013Peer Review Groups and Grant Study SectionsMemberDetailsRegular Member, Hepatobiliary Pathophysiology Study Sectionactivity American Association for the Study of Liver Disease
2008 - 2010Peer Review Groups and Grant Study SectionsMemberDetailsMember, Basic Research Committee
Honors
honor Member
02/17/2022National AwardAmerican Society for Clinical InvestigationDetailsUnited Stateshonor Fellow
02/17/2022International AwardAmerican Association for the Study of Liver DiseaseDetailsUnited Stateshonor Fellow
02/17/2022International AwardAmerican Gastroenterological AssociationDetailsUnited Stateshonor Member
02/17/2022National AwardAlpha Omega AlphaDetailsUnited States
News
Copy Link
Get In Touch
Copy Link
Contacts
Academic Office Number
Mobile Phone Number
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Administrative Support
Locations
Hepatology Clinic; Building 2; 4th Floor
Academic Office
VA Connecticut Healthcare
950 Campbell Avenue, Wing Building 2, Fl 4, Rm 140
West Haven, CT 06516
Business Office
203.932.5711 x7232Business Office Fax
203.937.3873